Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Genomic prostate score does not improve risk assessment

Key clinical point: The addition of a genomic prostate score to common clinical variables did not improve risk stratification during active surveillance.

Major finding: The hazard ratio for adverse pathology using the 17-gene Oncotype DX Genomic Prostate Score did not reach statistical significance in a multivariate model (hazard ratio, 1.17; P = .066).

Study details: A retrospective analysis of prospectively collected diagnostic biopsy samples from 432 men in the Canary Prostate Active Surveillance Study.

Disclosures: This work was supported by the Canary Foundation, the Department of Defense, the National Institutes of Health, and Genomic Health. The authors disclosed relationships with Genomic Health and other companies.


Lin DW et al. J Clin Oncol. 2020 Mar 4. doi: 10.1200/JCO.19.02267.